GSTM1 and chronic kidney disease: Clement et al. used a simulation model to examine the cost-effectiveness of four alternative Hb treatment targets (no ESA treatment, 9–10.9 g/dl, 11–12 g/dl, and > 12 g/dl) in a cohort of Canadian persons with CKD stage 4 or higher including those on dialysis [32].